Synthase of (-)-gemmarene A and preparation method thereof
A synthase protein with specific amino acid sequences from Micromonospora is used to produce (-)-germane A, overcoming the limitations of existing methods by enabling efficient synthesis of β-elemene through recombinant hosts, thus addressing the lack of a precursor for this clinically relevant compound.
Patent Information
- Application Number
- CN202310642522.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-01
- Publication Date
- 2024-12-03
AI Technical Summary
Current methods lack an effective synthase for producing the (-)-germane A compound, which is a precursor for the synthesis of β-elemene, a clinically significant sesquiterpenoid drug, as existing studies primarily focus on synthesizing its enantiomer (+)-germane A.
A synthase protein is developed with specific amino acid sequences, derived from Micromonospora, capable of converting farnesyl pyrophosphate into (-)-germane A, and is expressed in recombinant hosts like yeast or E. coli, utilizing engineered expression cassettes and vectors.
The synthase efficiently produces (-)-germane A, enabling the synthesis of β-elemene through a biological pathway, addressing the gap in existing technologies and providing a precursor for clinical applications.
Smart Images

Figure SMS_3 
Figure SMS_4 
Figure SMS_5
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to a synthase of (-)-germaene A and a preparation method thereof. Background Art
[0002] β-elemene is a volatile sesquiterpenoid compound with a tulip flavor. As a national Class II new drug, its oral emulsion and injection have achieved significant clinical therapeutic effects.
[0003] At present, the biological pathway generates the sesquiterpenoid compound Germacrene A through the catalysis of the precursor substance Farnesyl pyrophosphate (FPP) by Germacrene A synthase (GAS). Germacrene A can directly obtain β-elemene through a simple Cope rearrangement in vitro.
[0004] GAS is widely distributed in plants and microorganisms. Currently, many studies have been conducted to express GAS in recombinant engineering bacteria for the synthesis of (+)-germane A, and the corresponding Cope rearrangement product is (-)-β-elemene. However, researchers have discovered the existence of (+)-β-elemene (Research Progress on Analysis, Detection Methods and Preparation Technology of β-elemene, Huang Hanchang), as shown in Compound I: The corresponding precursor compound is (-)-germane A, as shown in compound II: However, the synthase that synthesizes (-)-germazine A has rarely been reported. Summary of the invention
[0005] The invention provides a (-)-germaene A synthase for producing (+)-β-elemene through a biological pathway.
[0006] The present invention provides a protein for producing (-)-germane A, wherein the protein comprises the following segments: 1) a polypeptide having an amino acid sequence of X1Y1X2Y2W; 2) a polypeptide having an amino acid sequence of X3Y3Y4Y5Y6L; 3) a polypeptide having an amino acid sequence of LY7Y8Y9X4Y 10 R polypeptide; 4) the amino acid sequence is Y 11 Y 12 Y 13 X5Y 14 of polypeptides.
[0007] Further, the amino acid of X1 may be Y, H, E, Q, preferably Q or E or H, preferably Q or E, preferably E; the amino acid of Y1 may be S, A, L, T, preferably S, A, more preferably S; the amino acid of X2 may be L, A, T, preferably A, T, more preferably A; the amino acid of Y2 may be C, A, D, preferably A; the amino acid of X3 may be R, G, A, P, preferably A, G, more preferably A; the amino acid of Y3 may be L, F, M, preferably L, F, more preferably L The amino acid of Y4 may be L or I, preferably L; the amino acid of Y5 may be E, D or A, preferably D or E, more preferably D; the amino acid of Y6 may be I or V, preferably V; the amino acid of Y7 may be A, H, D, R or K, preferably A or D, more preferably A; the amino acid of Y8 may be D, E or N, preferably D; the amino acid of Y9 may be L, I or M, preferably L or I, more preferably L; the amino acid of X4 may be R, C, W or I, preferably C, W or I, preferably C or I, preferably C; 10 The amino acid may be R, K, Q, L, N, preferably R; Y 11 The amino acid may be R, W, Y, or L, preferably R; Y 12 The amino acid may be N, A, V, K, Q, S, preferably A, S, V, preferably A, S, more preferably A; Y 13 The amino acid of X5 may be H, D, N, A, preferably D; the amino acid of X5 may be P, A, D, E, S, preferably P, E, D, S, preferably P, S, more preferably P; 14 The amino acid can be A, R, E, D, Q, L, preferably Q, A, preferably Q.
[0008] Furthermore, the present invention provides a protein for synthesizing (-)-gemaene A, wherein the protein has the following segments: 1) a polypeptide having an amino acid sequence of X1SX2AW; 2) a polypeptide having an amino acid sequence of X3LLDVL; 3) a polypeptide having an amino acid sequence of LADX4RR; 4) a polypeptide having an amino acid sequence of RADX5Q; wherein the amino acid of X1 can be E, Q, H, preferably E, Q, preferably E; the amino acid of X2 can be A, D, preferably A; the amino acid of X3 can be A, G, preferably A; the amino acid of X4 can be C, I, preferably C; the amino acid of X5 can be P, S, preferably P.
[0009] Furthermore, the amino acid sites of the segment 1) correspond to positions 28-31 shown in SEQ ID NO.4; the amino acid sites of the segment 2) correspond to positions 101-106 shown in SEQ ID NO.4; the amino acid sites of the segment 3) correspond to positions 125-131 shown in SEQ ID NO.4; and the amino acid sites of the segment 4) correspond to positions 203-208 shown in SEQ ID NO.4.
[0010] Furthermore, the present invention provides a protein for synthesizing (-)-germane A, whose amino acid sequence is shown in SEQ ID NO.4, wherein positions 28-31 of the protein are replaced by X1SX2AW, positions 101-106 are replaced by X3LLDVL, positions 125-131 are replaced by LADX4RR, and positions 203-208 are replaced by RADX5Q, wherein the amino acid of X1 can be E, Q, H, preferably E, Q, preferably E; the amino acid of X2 can be A, D, preferably A; the amino acid of X3 can be A, G, preferably A; the amino acid of X4 can be C, I, preferably C; the amino acid of X5 can be P, S, preferably P.
[0011] Furthermore, the amino acid sequence of the protein is as shown in SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14, SEQ ID NO.16, or has more than 90% or more than 99% homology thereto, preferably as shown in SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14, SEQ ID NO.16.
[0012] Furthermore, the protein is derived from Micromonospora, preferably from marine Micromonospora, preferably from marine Micromonospora AB-18-032, and the source refers to the different original source hosts of the gene.
[0013] The present invention further provides a nucleic acid sequence, which encodes the above amino acids.
[0014] Furthermore, the nucleic acid sequence is shown as SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.3, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, and SEQ ID NO.15.
[0015] Furthermore, the present invention provides a biological material related to any of the nucleotides and proteins described above, wherein the related biological material is any of the following:
[0016] A1) An expression cassette containing the above-mentioned nucleic acid molecule; preferably, the expression cassette comprises a promoter, the above-mentioned nucleic acid molecule and a terminator; preferably, the promoter is selected from TEF1 and PGK1, and the terminator is selected from CYC1 and ADH1.
[0017] A2) a host cell containing the nucleic acid molecule or any of the proteins described above or an expression cassette containing the nucleic acid molecule or comprising the recombinant vector; or,
[0018] A4) A recombinant vector, characterized in that the recombinant vector contains the above-mentioned nucleic acid molecule or expresses the above-mentioned encoding nucleic acid molecule, preferably the recombinant vector includes a promoter, the above-mentioned nucleic acid molecule and a terminator; preferably the promoter is selected from TEF1 and PGK1, and the terminator is selected from CYC1 and ADH1; preferably the sequence of the recombinant vector is shown in SEQ ID NO.18-SEQID NO.24.
[0019] A5) A transgenic plant comprising the above nucleic acid molecule or the above protein or the expression cassette or the recombinant vector or the host cell.
[0020] Furthermore, the present invention provides the use of any of the above-mentioned nucleotide sequences, protein sequences or related biological materials to catalyze the production of (-)-germaene A using farnesyl pyrophosphate (FPP) as a substrate.
[0021] Furthermore, the present invention provides a method for producing (-)-germane A, characterized in that the method comprises:
[0022] 1) Provide farnesyl pyrophosphate (FPP) precursor,
[0023] 2) contacting the FPP precursor with an enzyme, wherein the enzyme is used to catalyze the FPP precursor to generate (-)-germarene A, and the enzyme is preferably selected from the above-mentioned proteins.
[0024] Furthermore, the enzyme is an enzyme in a microorganism that provides a precursor heterologously.
[0025] Furthermore, the microorganism is yeast or Escherichia coli.
[0026] The present invention further provides a genetically modified host cell capable of producing (-)-germane A, comprising 1) one or more heterologous nucleic acids encoding one or more enzymes in the mevalonate pathway for producing farnesyl pyrophosphate; and 2) a heterologous nucleic acid encoding an enzyme for producing (-)-germane A, wherein the enzyme is selected from the above-mentioned protein. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Plasmid pESC-LEU-P PGK1 -P TEF1 -ERG20-T CYC1 Schematic diagram
[0028] Figure 2 For pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-T ADH1 Schematic diagram
[0029] Figure 3 For pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MmGAS-T ADH1 Schematic diagram
[0030] Specific implementation examples
[0031] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and specific implementation examples, but the implementation of the present invention is not limited thereto. The equivalent replacement, combination, improvement or modification of the technical solution of the present invention made by those skilled in the art based on the description of the present invention should be included in the protection scope of the present invention.
[0032] Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art. Unless otherwise specified, the reagents and materials used in the following examples are commercially available.
[0033] In the following examples, the fermentation product detection method is as follows:
[0034] Transfer the fermented bacterial liquid to 50mL centrifuge tubes, centrifuge to absorb an appropriate amount of n-dodecane in the upper layer, dilute it 10 times with ethanol, and detect it by GC-MS. Detection instrument: Agilent gas-mass spectrometer 7890B / 5977B. Chromatographic conditions: chromatographic column Agilent CycloSil-B (30m*0.25mm, 0.25μm), injection port temperature 250℃, injection volume 1μL, no splitting, carrier gas He, flow rate 2.3mL / min, column temperature program as shown in Table 1:
[0035] Table 1
[0036] Rate (℃ / min) Temperature(℃) Time (min) 0 90 3 2 120 0 30 245 5
[0037] Mass spectrometry conditions: EI ion source temperature 230 °C, quadrupole temperature 150 °C, electron energy 70 eV, scanning range 50-300 m / z.
[0038] Example 1
[0039] 1.1 Enzyme screening
[0040] According to the amino acid sequence of the terpene synthase MmGAS from Micromonospora marina in the NCBI database (nucleotide sequence as shown in SEQ ID NO.1, amino acid sequence as shown in SEQ ID NO.2), VmaTPS (amino acid sequence as shown in SEQ ID NO.3) was obtained. Beijing Liuhe BGI Technology Co., Ltd. optimized and synthesized the gene according to the codons of Saccharomyces cerevisiae, and inserted the optimized nucleotide sequence into the expression vector pESC-LEU-P PGK1 -P TEF1 -ERG20-T CYC1 (Refer to Figure 1-3 Schematic diagram of the preparation of pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-T ADH1 (see SEQ ID NO.18) and pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MmGAS-T ADH1
[0041] (See SEQ ID NO. 17). The names of the screened and synthesized genes and their annotation information in the database are shown in Table 2.
[0042] Table 2 Enzyme nomenclature and origin
[0043]
[0044] 1.2 Construction of yeast expression plasmid for VmaTPS point mutant
[0045] Plasmid pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-T ADH1As a template, point mutation primers were designed for full plasmid amplification (primers are shown in Table 4). The product was digested with DpnI at 37°C for 3h, and the target fragment was purified using the TaKaRa MiniBEST DNA Fragment Purification Kit Ver. 4.0 kit and transformed into the full gold Trans 5α competent cells, spread on LB-Amp resistance plates, grown at 37°C overnight, single clones were picked for colony PCR verification, positive clones were inoculated for culture, plasmids were extracted and sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing to verify the correct mutation. The enzyme sequence is shown in Table 3.
[0046] Table 3
[0047] Enzyme name Amino acid sequence of the enzyme Nucleotide sequence of enzyme VmaTPS-E28Q SEQ ID NO.6 SEQ ID NO.5 VmaTPS-E28H SEQ ID NO.8 SEQ ID NO.7 VmaTPS-A30D SEQ ID NO.10 SEQ ID NO.9 VmaTPS-A101G SEQ ID NO.12 SEQ ID NO.11 VmaTPS-C129I SEQ ID NO.14 SEQ ID NO.13 VmaTPS-P206S SEQ ID NO.16 SEQ ID NO.15
[0048] The obtained target plasmids were named
[0049] pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-E28Q-T ADH1 (SEQ ID NO.19),
[0050] pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-E28H-T ADH1 (SEQ ID NO.20),
[0051] pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-A30D-T ADH1 (SEQ ID NO.21), pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-A101G-T ADH1 (SEQ ID NO.22),
[0052] pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-C129I-T ADH1 (SEQ ID NO.23), pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1-VmaTPS-P206S-T ADH1 (SEQ ID NO.24).
[0053] Table 4
[0054] Primer Name Primer sequence (5' to 3') SEQ-A30D-F caagcatcagattcacgagcaacaacttcag SEQ-A30D-R aatctgatgcttgggctcaagaattggg SEQ-A101G-F caacaaaccggcagcagttggagataatctg SEQ-A101G-R ctgccggtttgttggatgttttggacttgcatg SEQ-C129I-F cttctaatcaaatcggccaaagctagacc SEQ-C129I-R gatttgattagaagagttagagcttacggtagac SEQ-E28H-F Agcagagtgacgagcaacaacttcagtgtc SEQ-E28H-R gctcgtcactctgctgcttgggctcaagaattg SEQ-E28Q-F cagattgacgagcaacaacttcagtgtc SEQ-E28Q-R gctcgtcaatctgctgcttgggctcaag SEQ-P206S-F attgtgagtctgctcttctttcggcagg SEQ-P206S-R gcagactcacaatgggccgctttggaattg
[0055] Example 2 Construction of yeast recombinant engineering bacteria
[0056] 2.1 Construction of Saccharomyces cerevisiae CEN11 strain
[0057] In order to realize the synthesis of germaene A in Saccharomyces cerevisiae, CEN.PK2-1D was selected for transformation, and gene editing was performed as shown in Table 5 below to finally obtain the Saccharomyces cerevisiae CEN11 strain.
[0058] Table 5
[0059]
[0060] 2.2 Preparation of competent CEN11 yeast
[0061] The CEN11 monoclone was picked up and transferred to 3 mL Synthetic Dropout Media (SD-His Ura) liquid culture medium and cultured at 30°C for 24 h. After being transferred to 50 mL Synthetic Dropout Media (SD-His Ura) liquid culture medium at a transfer volume of 5%, the cells were cultured until OD600 = 0.6-0.8, and the cells were collected and chemical transformation competent cells were prepared using the ZYMO Frozen-EZ Yeast TransformationII Kit.
[0062] 2.3 Construction of CEN11-GAS strain
[0063] Take the competent cells in 2.2 above and add plasmids
[0064] pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-T ADH1 , pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -MmGAS-T ADH1 , pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-E28Q-T ADH1 , pESC-LEU-PTEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-E28H-T ADH1 , pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-A30D-T ADH1 , pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-A101G-T ADH1 , pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-C129I-T ADH1 , pESC-LEU-P TEF1 -ERG20-T CYC1 -P PGK1 -VmaTPS-P206S-T ADH1 . Transformation was performed using the ZYMOFrozen-EZ Yeast Transformation II Kit, oscillated to mix, and incubated at 30°C for 45 min, oscillating once every 15 min. Spread on Synthetic Dropout Media (SD-His Ura) plates and cultured at 30°C for 2-3 days. The engineered bacteria obtained were named CEN11-VmaTPS, CEN11-MmGAS, CEN11-VmaTPS-E28Q, CEN11-VmaTPS-E28H, CEN11-VmaTPS-A30D, CEN11-VmaTPS-A101G,
[0065] CEN11-VmaTPS-C129I, CEN11-VmaTPS-P206S.
[0066] Example 3 Yeast system yield verification
[0067] 1) The yeast fermentation medium was prepared according to Example 3 of the prior art CN108060092B, and the amino acid content was adjusted appropriately.
[0068] 2) Saccharomyces cerevisiae engineered bacteria fermentation
[0069] The engineered bacteria obtained in Example 2.3 were selected and transferred to 3mL Synthetic Dropout Media (SD-His Ura) liquid culture medium, and cultured at 30°C, 250rpm for 24h; the bacterial solution cultured for 24h was transferred to 250mL Erlenmeyer flasks containing 20mL fermentation medium and 2mL n-dodecane at 5% transfer volume, and cultured at 30°C, 250rpm for 120h. Samples were collected and prepared for yield detection. The test results are shown in Table 6:
[0070] Table 6
[0071]
[0072]
Claims
1. A protein for producing (-)-germane A, characterized in that The protein comprises the following segments: 1) a polypeptide with an amino acid sequence of X1Y1X2Y2W; 2) a polypeptide with an amino acid sequence of X3Y3Y4Y5Y6L; 3) a polypeptide with an amino acid sequence of LY7Y8Y9X4Y 10 R polypeptide; 4) the amino acid sequence is Y 11 Y 12 Y 13 X5Y 14 of polypeptides.
2. The protein according to claim 1, characterized in that The amino acid of X1 is selected from Y, H, E, Q, preferably Q or E or H, preferably Q or E, preferably E; the amino acid of Y1 is selected from S, A, L, T, preferably S, A, more preferably S; the amino acid of X2 is selected from L, A, T, preferably A, T, more preferably A; the amino acid of Y2 is selected from C, A, D, preferably A; the amino acid of X3 is selected from R, G, A, P, preferably A, G, more preferably A; the amino acid of Y3 is selected from L, F, M, preferably L, F, more preferably L; the amino acid of Y4 is selected from L, I, preferably L; the amino acid of Y5 is selected from E, D, A, preferably D, E, more preferably D; the amino acid of Y6 is selected from I, V, preferably V; the amino acid of Y7 is selected from A, H, D, R, K, preferably A, D, more preferably A ; The amino acid of Y8 is selected from D, E, N, preferably D; The amino acid of Y9 is selected from L, I, M, preferably L, I, and more preferably L; The amino acid of X4 is selected from R, C, W, I, preferably C, W, I, preferably C, I, and preferably C; The amino acid of Y10 is selected from R, K, Q, L, N, and preferably R; The amino acid of Y11 is selected from R, W, Y, L, and preferably R; The amino acid of Y12 is selected from N, A, V, K, Q, S, preferably A, S, V, preferably A, S, and more preferably A; The amino acid of Y13 is selected from H, D, N, A, and preferably D; The amino acid of X5 is selected from P, A, D, E, S, preferably P, E, D, S, preferably P, S, and more preferably P; The amino acid of Y14 is selected from A, R, E, D, Q, L, and preferably Q.
3. The protein according to claim 1, characterized in that The protein has an amino acid sequence as shown in SEQ ID NO.4, characterized in that positions 28-31 of the amino acid sequence are replaced by X1SX2AW, positions 101-106 are replaced by X3LLDVL, positions 125-131 are replaced by LADX4RR, and positions 203-208 are replaced by RADX5Q, wherein the amino acid of X1 can be E, Q, H, preferably E, Q, preferably E; the amino acid of X2 can be A, D, preferably A; the amino acid of X3 can be A, G, preferably A; the amino acid of X4 can be C, I, preferably C; the amino acid of X5 can be P, S, preferably P.
4. The protein according to claim 1, characterized in that The amino acid sites of segment 1) correspond to positions 28-31 shown in SEQ ID NO.4; the amino acid sites of segment 2) correspond to positions 101-106 shown in SEQ ID NO.4; the amino acid sites of segment 3) correspond to positions 125-131 shown in SEQ ID NO.4; the amino acid sites of segment 4) correspond to positions 203-208 shown in SEQ ID NO.
4.
5. The protein according to claim 4, characterized in that The amino acid sequence of the protein is shown in SEQ ID NO.4, SEQ ID NO.6, SEQ ID NO.8, SEQ ID NO.10, SEQ ID NO.12, SEQ ID NO.14, SEQ ID NO.16 or has more than 90% or more than 99% homology thereto.
6. The protein according to any one of claims 1 to 5, characterized in that The protein is derived from Micromonospora, preferably from Micromonospora marine, preferably from Micromonospora marine AB-18-032.
7. A nucleic acid sequence characterized in that The nucleic acid sequence encodes the amino acids described in claims 1-6.
8. The nucleic acid sequence according to claim 7, characterized in that The nucleic acid sequence is as shown in SEQ ID NO.5, SEQ ID NO.7, SEQ ID NO.3, SEQ ID NO.9, SEQ ID NO.11, SEQ ID NO.13, SEQ ID NO.15 or has more than 90% or more than 99% homology thereto.
9. A biological material related to the nucleotide or protein according to any one of claims 1 to 8, wherein the related biological material is any one of the following: A1) An expression cassette containing the nucleic acid according to any one of claims 7-8; preferably, the expression cassette comprises a promoter, the above nucleic acid molecule and a terminator; preferably, the promoter is selected from TEF1 and PGK1, and the terminator is selected from CYC1 and ADH1. A2) A host cell comprising the nucleic acid molecule according to any one of claims 7 to 8 or the protein according to any one of claims 1 to 6 or an expression cassette containing the nucleic acid molecule or comprising the recombinant vector; or, A4) A recombinant vector, characterized in that the recombinant vector comprises the nucleic acid molecule described in any one of claims 7-8 or expresses the encoding nucleic acid molecule described in any one of claims 7-8, preferably the recombinant vector comprises a promoter, the above nucleic acid molecule and a terminator; preferably the promoter is selected from TEF1 and PGK1, and the terminator is selected from CYC1 and ADH1; preferably the recombinant vector sequence is shown in SEQ ID NO.18-SEQ ID NO.
24. A5) A transgenic plant comprising the nucleic acid molecule according to any one of claims 7 to 8, or the protein according to any one of claims 1 to 6, or the expression cassette, or the recombinant vector, or the host cell.
10. Use of the nucleotide sequence, protein sequence or related biological material according to any one of claims 1 to 9 to catalyze the production of (-)-germaene A using farnesyl pyrophosphate (FPP) as a substrate.
11. A method for producing (-)-germaene A, characterized in that The method comprises: 1) Provide farnesyl pyrophosphate (FPP) precursor, 2) contacting the FPP precursor with an enzyme for catalyzing the production of (-)-germane A from the FPP precursor, preferably the enzyme is selected from the protein according to any one of claims 1 to 6, preferably the enzyme is an enzyme in a microorganism that heterologously provides the precursor, more preferably the microorganism is yeast or Escherichia coli.
12. A genetically modified host cell capable of producing (-)-germane A, characterized in that The invention comprises 1) one or more heterologous nucleic acids encoding one or more enzymes for producing farnesyl pyrophosphate in the mevalonate pathway; and 2) a heterologous nucleic acid encoding an enzyme for producing (-)-germarene A, wherein the enzyme is preferably selected from the protein of any one of claims 1 to 6.
